Finanzen von ArriVent BioPharma, Inc. (AVBP)AVBPArriVent BioPharma, Inc.

Evaluating the bottom line, ArriVent BioPharma, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -53.10%, provide a clear picture of how effectively AVBP converts its operational activities into shareholder value.

In the context of the broader market, AVBP competes directly with industry leaders such as ARTV and USNA. With a market capitalization of $832.81M, it holds a leading position in the sector. When comparing efficiency, AVBP's gross margin of N/A stands against ARTV's N/A and USNA's 78.35%. Such benchmarking helps identify whether ArriVent BioPharma, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a net income loss of $49.89 million in Q2 2026, and the forward P/E ratio is 0, indicating no earnings expected in the near term.